Empagliflozin improves Cognitive impairment in Frail Diabetics with HFpEF Italy: Empagliflozin a SGLT2 inhibitor improves the cognitive and Physical impairment in frail older adults Heart failure with Preserved Ejection Fraction and Type 2 Diabetes a recent study has found. It is to be noted that this study was published in Journal Diabetes care on March […]
Diabetes and Endocrinology
Chest CT Lesion Size in Acute COVID-19 Can Predict Late Myocardial Injury NOTE :The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed. KEY POINTS: 1:Left ventricular (LV) and right ventricular (RV) global longitudinal strain (GLS) were reduced in patients with severe pulmonary lesions (at […]
COVID-19 Study Updates
Gastaut Syndrome – FDA Approved New Med for Lennox The US Food and Drug Administration (FDA) has approved fenfluramine (Fintepla) oral solution, a Schedule IV controlled substance, for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children aged 2 years and older, the company has announced. Fenfluramine is already approved in the US […]
New Drug Approvals